According to research, Combigan Eye Drops effectively lowers IOP and reduces the discomfort associated with the necessity of daily instillations
In an attempt to eliminate the causes of non-hypertensive patients, treatment instillation of drops ophthalmologists reviewed the results of a recently completed postmarketing studies showing unexpected opportunities not only efficient but also comfortable treatment of glaucoma.
According to data obtained during the prospective multicenter open clinical trial Combigan Eye Drops (brimonidina tartrate + timolol maleate, Allergan, Irvine, USA), the drug lowers intraocular pressure in different situations – in patients with glaucoma, which was first given treatment already receiving antihypertensive therapy or use Combigan Eye Drops as an adjunct to other medicines. And the patients themselves, and doctors say that in general the drug was well tolerated and easy to use. The results of this study were presented as a poster at the World Congress on Glaucoma-2009 in Boston (“Evaluating the effectiveness, tolerability and safety of ophthalmic solution 0.2% and 0.5% brimonidina timolol).
These data are particularly important in light of the notorious problem of non-adherence instillation of eye drops. According to Associate Professor Carlos Buznego from the Institute of eyes Beskom Palmer (Miller School of Medicine University of Miami, Miami, USA), the tolerability of drugs plays an important role in the treatment of glaucoma and, moreover, is one of the key factors in the patient’s consent to the scheme of therapy. Of all the eye disease glaucoma status is such that to achieve full agreement with the treatment is sometimes very difficult, because it is asymptomatic, and the vision is irreversibly lost.
Effectiveness Combigan Eye Drops as antihypertensives high – the average IOP decreased from 21 mmHg to 16,3 mm Hg, ie, more than 20%. The greatest effect was observed in the group of persons to whom treatment is scheduled for the first time: in 2 months the IOP decreased from baseline (25.5 mm Hg) on average by 9.3 mmHg It is particularly important that changes are characterized by statistically significant in all subgroups of patients. It turns out that these data refute the hypothesis put forward earlier that if the substitute Combigan Eye Drops other antihypertensives, the IOP decrease is not as noticeable. However, demonstrated that Combigan Eye Drops and effective as a replacement drops, used by patients before.
High efficiency combined with very good tolerability. The second month assessment Combigan Eye Drops as “good,” “very good” and “excellent” preparations yield about 97% of patients. Over 55% of people also claim to comfort its application to the eye compared with other drugs. In all likelihood, this is due to a lower incidence of side effects, such as the emergence of a sense of burning and stinging, eye redness and blurred vision. “Although the decrease in the average level of IOP plays a very important role in assessing the effectiveness of any anti-hypertensive drug, its ease of use, not least judged by the degree of patient satisfaction. I was somewhat surprised by this aspect, “- says Dr. Buznego.
Other experts also believe in comfort and effectiveness Combigan Eye Drops, which in combination provides excellent clinical results. Moreover, its effect is manifested in patients of all three subgroups, which were discussed above as well as in combination with other drugs. According to one study’s authors, Dr. Ehsan Sadri (Newport Beach, USA), IOP was expected, although not in such a great extent. Major side effects of medication – redness of the eyes (2,5% of cases), burning sensation in the eye (2.3%), xerostomia (1.5%) and blurred vision (1.3%).
Attention is drawn to the fact that the best outcomes were reported in patients with IOP levels of 22 to 28 mm Hg. Art. Consequently, the higher the initial IOP, the more it decreases. GPs also give a positive assessment Combigan Eye Drops. Approximately 95% of the performance of IOP against instillation of this drug can control at least partly. And 90% of ophthalmologists say that the acceptability and tolerability of patients can be called at least a good one.
